Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Pancreatic cancer, treatment

Ough, M., A. Lewis, E.A. Bey, et al. 2005. Efficacy of beta-lapachone in pancreatic cancer treatment Exploiting the novel, therajjeutic target NQOl. Cancer Biol. Ther. 4(1) 95-102. [Pg.849]

Trickier WJ, Khurana J, Nagvekar AA, Dash AK (2010) Chitosan and glyceryl monooleate nanostructures containing gemcitabine potraitial delivtay system for pancreatic cancer treatment. AAPS PharmSciTech 11(1) 392-401... [Pg.89]

The usual dose consists of 1000 mg/m2 i.v. It is the most active single agent for treating pancreatic cancer, and it is used as a fust-line treatment for both pancreatic and small cell lung cancers. The dose-limiting toxicity is bone marrow suppression. [Pg.151]

Cancer treatment is a multimodality treatment, i.e., surgery is combined with radiotherapy and antineoplastic chemotherapy. The latter treatment mode is used mainly for cancers which have disseminated. Different forms of cancer differ in their sensitivity to chemotherapy with antineoplastic agents. The most responsive include lymphomas, leukemias, choriocarcinoma and testicular carcinoma, while solid tumors such as colorectal, pancreatic and squamous cell bronchial carcinomas generally show a poor response. The clinical use of antineoplastic agents is characterized by the following principles. [Pg.157]

In phase I clinical trials 47 patients, all of whom had previously failed standard treatments for solid tumors, received the drug in the UK, Italy, and Switzerland on three different schedules.123,124 Dose-limiting toxicities have been defined as bone marrow depression and diarrhea. The latter is treatable with loperamide. Signs of biological activity were seen. Notably one patient with metastatic pancreatic cancer showed a partial response (for 4 months) and two further patients, one with metastatic melanoma and one with bronchoalveolar carcinoma, also showed partial responses. In a phase I trial in combination with 5-FU, a partial response in breast cancer was observed.125 Furthermore, a reduction in tumor marker levels was observed in two patients, one with ovarian cancer, and one with colon cancer. Phase II studies have shown partial responses in cisplatin-resistant ovarian and nonsmall-cell lung cancer.126,127 The indications are that the profile of clinical activity is different and complementary to the mononuclear platinum agents. [Pg.821]

Metal-texaphyrin complexes such as 55 selectively accumulate in tumor cells (240) (see Section III). Complex 55 readily undergoes aone-electron reduction (Ei/2 = 0.08 V vs NHE), forming a free radical which is capable of damaging DNA. Because of the high electron affinity of 55, it may prolong the lifetime of HO- radicals formed by radiolysis of water. Complex 55 is now in phase II clinical trials for the treatment of brain tumors and lung, head, neck, and pancreatic cancer. [Pg.222]

A number of medical conditions are associated with high rates of depression (see Table 3.4). In some instances, the distinction between MDD and depression due to a general medical condition is largely academic with little bearing on treatment selection. For example, pancreatic cancer may induce depression directly through the release of tumor-secreted substances however, depression in the pancreatic cancer patient is treated with conventional antidepressant medications. In other cases, the diagnostic distinction bears important treatment implications. One commonly cited example is depression occurring in association with hypothyroidism. Patients with depression and hypothyroidism do not respond to antidepressant treatment alone but require a thyroid hormone supplement. [Pg.43]

Erlotinib has been approved by the FDA for second- or third-line treatment of NSCLC [45], and in combination with gemcitabine as first-hne therapy for pancreatic cancer [46]. Since the majority of human studies with erlotinib have been in NSCLC, the clinical discussion will focus on this indication. When dosed oraUy once a day at 150mg/day in an uncontrolled phase II study, erlotinib resulted in a 12% objective response rate in second-or third-hne NSCLC patients [47,48]. In first-hne NSCLC, phase III studies of standard-of-care with or without erlotinib failed to show a chnical benefit in objective response rate, time to progression, or survival for the erlotinib-treated group. However, in a large placebo-controlled phase III trial, erlotinib provided a clear survival benefit as single agent in second- or third-hne treatment of NSCLC, which subsequently led to FDA approval [45,49]. In that trial, patients were randomized to receive erlotinib in addition to supportive... [Pg.97]

While no in vivo activity has been reported in an Abl-dependent CML model, AZD0530 was active in a xenograft model using Src-transformed NIH 3T3 cells and in an orthotopic model of pancreatic cancer, two Src-dependent models. The results of a Phase I trial in normal volunteers have been disclosed and AZD0530 was tolerated when administered at doses of up to 250 mg [156,157]. While it appears that the initial efficacy trial for AZD0530 will be as an anti-invasive agent for the treatment of metastatic bone disease, this compound probably also has potential for use in CML. [Pg.432]

Resectable pancreatic cancer GITSG Radiation alone (40 Gy) + 5-FU No adjustment treatment 21.0 moa 10.9 mo"... [Pg.37]

The treatment of pancreatic cancer continues to be challenging. Standard treatment with 5-FU-based regimens and radiation has resulted in 5-yr survival rates of 15-20%. In locally advanced and metastatic patients, the median survival is less than 10 mo. As such, investigators have tried to improve outcomes by incorporating novel agents like gemcitabine into therapy (Table 5). [Pg.119]

Gy of radiation to the pancreas was tolerable in pancreatic cancer patients with a 20% response rate in 15 evaluable patients. Three out of eight patients with a minimum of 12 mo follow up were alive (65). Based on these data, Cancer and Leukemia Group B (CALGB) conducted a phase II trial to examine the efficacy of concurrent twice-weekly Gemcitabine (40 mg/m2) and radiation (50.4 Gy) treatment regimen in patients with locally advanced pancreatic cancer. The preliminary result showed 55% of the... [Pg.119]

Wilkowski R, Heinemann V, Rau H, et al. Radiochemotherapy including gemcitabine and 5-FU for treatment of locally advanced pancreatic cancer. Proc Am Soc Clin Oncol 2000 19 276a. [Pg.125]

Surgery, radiotherapy, and chemotherapy are the treatment options for patients having pancreatic cancer. These treatment modalities have had a limited impact. [Pg.259]

Despite the potential for better local-regional control using preoperative or adjuvant chemoradiotherapy, the prognosis of pancreatic cancer remains poor. Treatment failure is primarily due to distant metastases. Also, the progress in the treatment of pancreatic cancers is hindered by the absence of effective systemic agents. New approaches continue to be developed that hopefully will alter the natural history of this disease. [Pg.261]

Gemcitabine, a new pyrimidine antimetabolite, is of substantial interest as a radiosensitizer in the treatment of pancreatic cancer. An ongoing multi-institutional Phase II study of preoperative EBRT and concomitant gemcitabine therapy for resectable adenocarcinoma will provide useful information (57-60). [Pg.261]

The importance of lymphocytes in cancer treatments based on LPS had been evoked by Parr et al. [61], Their role was later emphasized in A/J mice bearing SA-1 sarcoma or BALB/c mice bearing Meth A fibrosarcoma, treated with LPS [95], and in BDEX rats bearing PROb colon carcinoma, treated with bacterial extracts [96], Furthermore, SCID mice treated with intraperitoneal (i.p.) injections of LPS are unable to reject Meth A fibrosarcoma [96], However, lipid A treatment was efficient in nude mice bearing human pancreatic tumors [134]. [Pg.530]

However, several types of cancer do not respond well to treatment. For example, the majority of metastatic cancers cannot be cured by current chemotherapeutic methods or by any other type of treatment.11 In addition, some of the most common forms of adult neoplastic disease are difficult to treat by using anticancer drugs. As indicated in Table 36-9, the number of deaths associated with colorectal, prostate, and breast cancer is unacceptably high, and the mortality rate for lung cancer and pancreatic cancer is well over 90 percent in both men and women. [Pg.583]


See other pages where Pancreatic cancer, treatment is mentioned: [Pg.149]    [Pg.344]    [Pg.189]    [Pg.373]    [Pg.231]    [Pg.13]    [Pg.157]    [Pg.195]    [Pg.364]    [Pg.394]    [Pg.23]    [Pg.68]    [Pg.81]    [Pg.107]    [Pg.109]    [Pg.119]    [Pg.119]    [Pg.121]    [Pg.122]    [Pg.122]    [Pg.460]    [Pg.716]    [Pg.581]    [Pg.649]    [Pg.38]    [Pg.240]    [Pg.377]   
See also in sourсe #XX -- [ Pg.259 ]

See also in sourсe #XX -- [ Pg.2290 ]

See also in sourсe #XX -- [ Pg.598 ]




SEARCH



Cancer treatment

Pancreatic cancer

© 2024 chempedia.info